GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
A surface charge is an electric charge present on a two-dimensional surface. These electric charges are constrained on this 2-D surface, and surface charge density, measured in coulombs per square meter (C•m−2), is used to describe the charge distribution on the surface. The electric potential is continuous across a surface charge and the electric field is discontinuous, but not infinite; this is unless the surface charge consists of a dipole layer. In comparison, the potential and electric field both diverge at any point charge or linear charge. In physics, at equilibrium, an ideal conductor has no charge on its interior; instead, the entirety of the charge of the conductor resides on the surface. However, this only applies to the ideal case of infinite electrical conductivity; the majority of the charge of an actual conductor resides within the skin depth of the conductor's surface. For dielectric materials, upon the application of an external electric field, the positive charges and negative charges in the material will slightly move in opposite directions, resulting in polarization density in the bulk body and bound charge at the surface. In chemistry, there are many different processes which can lead to a surface being charged, including adsorption of ions, protonation or deprotonation, and, as discussed above, the application of an external electric field. Surface charge emits an electric field, which causes particle repulsion and attraction, affecting many colloidal properties.
== Philosophy == Adorno's work sets out from a central insight he shares with all early 20th-century avant-garde art: the recognition of what is primitive in ourselves and the world itself. Neither Picasso's fascination with African sculpture nor Mondrian's reduction of painting to its most elementary component—the line—is comprehensible outside this concern with primitivism, which Adorno shared with the century's most radical art. At that time, the Western world, beset by world wars, colonialist consolidation, and accelerating commodification, sank into the very barbarism civilization had prided itself in overcoming. According to Adorno, society's self-preservation had become indistinguishable from the socially sanctioned self-sacrifice of "primitive" people, the primitive aspects of the ego, and those primitive, mimetic desires found in imitation and sympathy. Adorno's theory proceeds from an understanding of this primitive quality of reality that seeks to counteract whatever aims either to repress this primitive aspect or to further those systems of domination set in place by this return to barbarism. From this perspective, Adorno's writings on politics, philosophy, music, and literature are a lifelong critique of the ways in which each tries to justify self-mutilation as the necessary price of self-preservation.
=== Nomenclature === Often amide refers to carboxamide, and often amide refers to the anions R2N- and their derivatives. Tetrakis(dimethylamido)titanium (Ti(N(CH3)2)4) illustrates the ambiguity of the terminology.
Urinalysis — assessment of the visual properties of the urine, chemical evaluation using urine test strips, and microscopic examination Urine creatinine, creatinine clearance — used to assess kidney function Albumin/creatinine ratio — used to diagnose microalbuminuria Urine osmolality — measure of the solute concentration of urine Urine specific gravity ― another measure of urine concentration Urine electrolyte levels — measurement of electrolytes such as sodium and potassium in urine Urine anion gap — used to distinguish between some causes of metabolic acidosis
Sources: en.wikipedia.org
== Popular culture == The 1977 movie Clark, had Olofsson as co-writer on the script. Folkhemsdesperadon (2001) is a documentary with an interview with Olofsson. Norrmalmstorgsdramat inifrån (2003) is an interview with the bank-robber Jan-Erik Olsson, who demanded that Olofsson be allowed to come to the bank. In the film Norrmalmstorg (2003), Olofsson is portrayed by Shanti Roney. The podcast Criminal spoke with Olofsson about the Norrmalmstorg robbery in their episode "Hostage." In January 2020, Sveriges Television aired the documentary Clark - en rövarhistoria. The documentary was criticized for portraying Olofsson like an idol, and because it had been produced by Alexander Eriksson, one of the convicted robbers from the Västberga helicopter robbery. On 11 May 2020, Netflix announced Clark, a limited six-episode drama series about Clark Olofsson. The series, directed by Jonas Åkerlund, aired in May 2022. Olofsson is played by Bill Skarsgård.
The synthesis of the first true heteroleptic metal carbonyl complex was performed by Paul Schützenberger in 1868 by passing chlorine and carbon monoxide over platinum black, where dicarbonyldichloroplatinum (Pt(CO)2Cl2) was formed. Ludwig Mond, one of the founders of Imperial Chemical Industries, investigated in the 1890s with Carl Langer and Friedrich Quincke various processes for the recovery of chlorine which was lost in the Solvay process by nickel metals, oxides, and salts. As part of their experiments the group treated nickel with carbon monoxide. They found that the resulting gas colored the gas flame of a burner in a greenish-yellowish color; when heated in a glass tube it formed a nickel mirror. The gas could be condensed to a colorless, water-clear liquid with a boiling point of 43 °C. Thus, Mond and his coworker had discovered the first pure, homoleptic metal carbonyl, nickel tetracarbonyl (Ni(CO)4). The unusual high volatility of the metal compound nickel tetracarbonyl led Kelvin to the statement that Mond had "given wings to the heavy metals". The following year, Mond and Marcellin Berthelot independently discovered iron pentacarbonyl, which is produced by a similar procedure as nickel tetracarbonyl. Mond recognized the economic potential of this class of compounds, which he commercially used in the Mond process and financed more research on related compounds. Heinrich Hirtz and his colleague M. Dalton Cowap synthesized metal carbonyls of cobalt, molybdenum, ruthenium, and diiron nonacarbonyl. In 1906 James Dewar and H. O.
=== Drug-Drug Interaction === Drug-Drug Interaction models explore the impact of interactions between different drugs on their pharmacokinetics or pharmacodynamics. These models help predict the effects of co-administered drugs on each other, aiding in the identification of potential risks and the adjustment of dosages in the presence of multiple medications.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.